We serve Chemical Name:4-(Piperidine-1-carbonyl)phenylboronic acid CAS:389621-83-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(Piperidine-1-carbonyl)phenylboronic acid
CAS.NO:389621-83-4
Synonyms:[4-(piperidine-1-carbonyl)phenyl]boronic acid;MFCD03411951
Molecular Formula:C12H16BNO3
Molecular Weight:233.07100
HS Code:2933399090
Physical and Chemical Properties:
Melting point:150-154ºC
Boiling point:456.1ºC at 760mmHg
Density:1.22g/cm3
Index of Refraction:1.577
PSA:60.77000
Exact Mass:233.12200
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like [4-(piperidine-1-carbonyl)phenyl]boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD03411951 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[4-(piperidine-1-carbonyl)phenyl]boronic acid Use and application,MFCD03411951 technical grade,usp/ep/jp grade.
Related News: It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. diethyl 2-oxo-3-phenylbutanedioate manufacturers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. 1-(4-fluorophenyl)imidazole-4-carboxylic acid suppliers With over 80 years of experience developing and manufacturing small molecules, UQUIFA has not only the knowledge and tools to successfully execute transfer activities but also the track record of success with several crucial drug commercialization,” Gurnurkar says. 2′,3′-Di-O-acetyladenosine vendor & factory With over 80 years of experience developing and manufacturing small molecules, UQUIFA has not only the knowledge and tools to successfully execute transfer activities but also the track record of success with several crucial drug commercialization,” Gurnurkar says. ,Immunocompromised people account for roughly 2.7% of U.S. adults including patients who’ve received an organ transplant, living with HIV or have received active or recent treatment for cancer, Oliver said.
